What drugs are available in Hengrui Pharma to treat atopic dermatitis?

In March, 2023, Hengrui Pharma and its subsidiary, Ruishi Bio, released the third phase clinical research results of JAK 1 inhibitor Imassi tinib at the important branch of the annual meeting of the American Academy of Dermatology (AAD). The results show that imatinib has excellent efficacy and safety, which makes it competitive in the atopic dermatitis market. If it is successfully marketed, it is very likely to quickly become the main JAK 1 inhibitor in the field of atopic dermatitis treatment.